Global Patent Index - EP 2542249 A4

EP 2542249 A4 20130807 - METHODS AND COMPOSITIONS TO SUPPORT TISSUE INTEGRATION AND INOSCULATION OF TRANSPLANTED TISSUE AND TRANSPLANTED ENGINEERED PENILE TISSUE WITH ADIPOSE STROMAL CELLS

Title (en)

METHODS AND COMPOSITIONS TO SUPPORT TISSUE INTEGRATION AND INOSCULATION OF TRANSPLANTED TISSUE AND TRANSPLANTED ENGINEERED PENILE TISSUE WITH ADIPOSE STROMAL CELLS

Title (de)

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR UNTERSTÜTZUNG VON GEWEBEINTEGRATION UND INOKULATION VON TRANSPLANTIERTEM GEWEBE UND TRANSPLANTIERTEM GEZÜCHTETEM PENISGEWEBE MIT STROMAZELLEN AUS FETTGEWEBE

Title (fr)

PROCÉDÉS ET COMPOSITIONS DESTINÉS À FAVORISER L'INTÉGRATION DE TISSU ET L'INOCULATION DE CELLULES STROMALES ADIPEUSES DANS UN TISSU TRANSPLANTÉ ET UN TISSU PÉNIEN FABRIQUÉ ET TRANSPLANTÉ

Publication

EP 2542249 A4 20130807 (EN)

Application

EP 10847139 A 20100305

Priority

US 2010026407 W 20100305

Abstract (en)

[origin: WO2011109026A1] The present invention generally relates to methods, compositions and uses thereof for enhancing vascularization of a tissue or cell transplant for transplantation into a subject. In particular, one aspect of the present invention provides methods and compositions comprising the use of a population of stromal vascular fraction (SVF) cells to encapsulate or surround a tissue or cell transplant to enhance vascularization of the tissue or cell transplant. Another aspect of the present invention provides methods and compositions for enhancing vascularization of a tissue or cell transplant by combining a population of SVF cells with a tissue or cell transplant to form a transplant mixed with SVF cells. Another aspect provides a composition comprising an engineered corpus cavernosa tissue comprising SVF cells and corpus cavernosa cells, wherein the SVF cells can be mixed with or encasing the corpus cavernosa cells, and methods of uses thereof, for example in method for the treatment of impotence and erectile dysfunction and/or enhance or contruct a penis. In some embodiments, the SVF cells can be generically engineered to secrete therapeutic proteins or pro-angiogenic factors.

IPC 8 full level

A61K 35/12 (2006.01); A61K 35/28 (2015.01); A61K 35/33 (2015.01); A61K 35/44 (2015.01); A61K 35/48 (2015.01)

CPC (source: EP)

A61K 35/28 (2013.01); A61K 35/33 (2013.01); A61K 35/44 (2013.01); A61K 35/48 (2013.01); A61P 15/00 (2017.12); A61P 41/00 (2017.12)

Citation (search report)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)

WO 2011109026 A1 20110909; EP 2542249 A1 20130109; EP 2542249 A4 20130807; EP 2926821 A1 20151007; EP 2926821 B1 20191225

DOCDB simple family (application)

US 2010026407 W 20100305; EP 10847139 A 20100305; EP 15164924 A 20100305